Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation

Syed M. Kazmi, Maliha Nusrat, Hilal Gunaydin, Amanda M. Cornelison, Nina Shah, Partow Kebriaei, Yago Nieto, Simrit Parmar, Uday R. Popat, Betul Oran, Jatin J. Shah, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash, Qaiser Bashir

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background Conventional cytogenetics and interphase fluorescence in-situ hybridization (FISH) identify a high-risk multiple myeloma population characterized by poor response and short survival. Patients and Methods We compared outcomes between high-risk and standard-risk myeloma patients who underwent autologous hematopoietic stem-cell transplantation (auto-HCT) at our institution between January 2005 and December 2009. High-risk myeloma was defined as -13/del(13q) or hypodiploidy in at least 2 metaphases of conventional cytogenetics, or -17/del(17p), t(4;14), t(14;16), t(14;20), hypodiploidy (< 45 chromosomes excluding -Y), or chromosome 1 abnormalities (+1q, -1p, t(1;x)) on FISH or conventional cytogenetics. Results Of 670 myeloma patients, 74 (11%) had high-risk myeloma. These high-risk patients had significantly lower overall response rates (74% vs. 85%; P <.01), shorter median progression-free survival (10.3 vs. 32.4 months; P <.001), and shorter overall survival (28 months vs. not reached; P <.001) than the standard-risk patients. Having only 1 high-risk cytogenetic abnormality or experiencing at least very good partial remission after auto-HCT independently predicted improved progression-free survival and overall survival (P <.05) in high-risk patients. Conclusion Even in an era of novel therapies, cytogenetically identified high-risk myeloma patients have worse prognoses than standard-risk myeloma patients after auto-HCT, and having more than 1 high-risk cytogenetic abnormality further reduces survival.

Original languageEnglish (US)
Pages (from-to)687-693
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number11
DOIs
StatePublished - Nov 2015

Keywords

  • Cytogenetics
  • Multiple myeloma
  • Prognosis
  • Risk stratification
  • Stem-cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    Kazmi, S. M., Nusrat, M., Gunaydin, H., Cornelison, A. M., Shah, N., Kebriaei, P., Nieto, Y., Parmar, S., Popat, U. R., Oran, B., Shah, J. J., Orlowski, R. Z., Champlin, R. E., Qazilbash, M. H., & Bashir, Q. (2015). Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clinical Lymphoma, Myeloma and Leukemia, 15(11), 687-693. https://doi.org/10.1016/j.clml.2015.07.641